Multiple Sclerosis Journal · 1999 · 90 citations · 30 references
MedicineNeurobiologyPharmacologyInflammationInnate ImmunityNeuroimmunologyAnti-inflammatory PharmacologyBlood-brain Barrier PharmacologyCytokine BiologyCytokine RegulationMicroglia BiologyNeuroinflammationBlood-brain Barrier PermeabilityInflammatory Cytokine ProductionMicroglia ActivationMicroglia ModulationMicroglia-blood-brain Barrier InteractionsNeuroinflammatory Cytokine ResponsesNeuroinflammatory CytokinesPhosphodiesterase Signaling
Type III and IV phosphodiesterase inhibitors (PDEIs) have recently been shown to suppress the production of TNF-alpha in several types of cells. In the present study, we have shown that all the types of PDEIs, from type I- to V-specific and non-specific, suppress the production of TNF-alpha by mouse microglia stimulated with lipopolysaccharide (LPS) in a dose-dependent manner. Certain combinations of three different types of PDEIs synergistically suppressed TNF-alpha production by microglia at a very low concentration (1 microM). Since some PDEIs reportedly pass through the blood-brain barrier (BBB), the combination of three PDEIs may be worth trying in neurological diseases, such as multiple sclerosis and HIV-related neurological diseases in which TNF-alpha may play a critical role. Some PDEIs also suppressed interleukin-I (IL-I) and IL-6 production by mouse microglia stimulated with LPS. In contrast, the production of IL-10, which is known to be an inhibitory cytokine, was upregulated by certain PDEIs. The suppression of TNF-alpha and induction of IL-10 were confirmed at the mRNA level by RT-PCR. PDEIs may be useful anti-inflammatory agents by downregulating inflammatory cytokines and upregulating inhibitory cytokines in the central nervous system. (CNS).
30